Video Experimental Relacionado
Updated: Jun 27, 2026
13:10
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
Published on: September 25, 2016
El microembolismo cerebral es bloqueado por tirofibán, un selectivo no péptido glicoproteína plaquetaria IIb / IIIa
Ulrich Junghans1, Mario Siebler
1Department of Neurology, Heinrich-Heine University, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Circulation
|May 14, 2003
Resumen
El tirofibán, un antagonista de la glicoproteína IIb/IIIa, eliminó eficazmente las señales microembólicas (MES) en pacientes con enfermedad de la arteria carótida. Esto sugiere que las unidades de plaquetas-fibrinógeno son clave para los microembolismos cerebrales, y los antagonistas GPIIb/IIIa pueden reducir el riesgo de accidente cerebrovascular.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacología Farmacología.
Sus antecedentes:
- Las señales microembólicas (MES) detectadas por la ecografía Doppler transcraneal indican el riesgo de accidente cerebrovascular en la enfermedad de la arteria carótida.
- Comprender la composición del MES es crucial para las estrategias de prevención del accidente cerebrovascular.
Objetivo del estudio:
- Para investigar la composición in vivo de las señales microembólicas (MES).
- Para evaluar la eficacia del tirofibán, un antagonista del receptor de la glicoproteína IIb/IIIa, en la inhibición de la MES.
Principales métodos:
- Veinticuatro pacientes con embolia arterial reciente y altas tasas de MES recibieron tirofibán.
- Las tasas de MES fueron monitoreadas antes, durante y después de la infusión de tirofibano.
- También se evaluó el efecto de la superposición de agentes antiplaquetarios orales.
Principales resultados:
- Tirofiban redujo las tasas de MES de una mediana de 38 a cero en todos los pacientes.
- El efecto inhibidor fue reversible tras el cese de la infusión de tirofibán.
- Seis pacientes que recibían agentes antiplaquetarios orales superpuestos se mantuvieron MES-negativos.
Conclusiones:
- Los microembolismos cerebrales parecen ser embolias sólidas compuestas principalmente por unidades de plaquetas y fibrinógeno.
- Los antagonistas de la glicoproteína IIb/IIIa muestran potencial para reducir el riesgo isquémico en la enfermedad carotídea inestable.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...